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Abstract The AMP-activated protein kinase is a sensor of
cellular energy status that is found in all eukaryotic cells. It
is activated by rising AMP and falling ATP by a complex
mechanism that results in an ultrasensitive response. The func-
tions of the di¡erent domains on the three subunits of the KLQ
heterotrimer are slowly being unravelled, and a recent develop-
ment has been the identi¢cation of a glycogen-binding domain
on the L subunit. Along with ¢ndings that high cellular glycogen
represses kinase activation, this suggests that the system may be
a sensor of glycogen content as well as of AMP and ATP. New
insights have been obtained into the sequence and structural
features by which the kinase recognises its downstream target
proteins, and these are discussed. Once activated by depletion of
cellular energy reserves, the kinase switches on ATP-producing
catabolic pathways and switches o¡ ATP-consuming processes,
both via direct phosphorylation of regulatory proteins and via
indirect e¡ects on gene expression. A survey of the range of
downstream targets for this important signalling pathway is
presented.
% 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
One of the most fundamental parameters that all living cells
must maintain is a high ratio of ATP to ADP. The equilibri-
um ratio for ATP:ADP under intracellular conditions is
around 1037 :1, but living cells typically maintain this ratio
at something like 10:1, i.e. eight orders of magnitude away
from equilibrium. This non-equilibrium state of ATP and
ADP is analogous to that of the chemicals in a fully charged
electrical cell or battery, and just like the latter can be used to
drive energy-requiring processes. In animal cells ADP and
phosphate are converted to ATP (charging the battery) by
catabolic reactions, i.e. glycolysis and oxidative phosphoryla-
tion. Almost every other cellular process requires energy and
converts ATP to ADP and phosphate (or, in a few cases, to
AMP and pyrophosphate), thus discharging the battery. The
fact that the cellular ATP:ADP ratio is usually maintained
within very narrow limits indicates that the rates of these
energy-requiring processes in the cell are balanced almost per-
fectly by the rate of catabolism. However, if one stops to
think about it, there is no a priori reason why this should
be so. The explanation has to be that there are sophisticated
regulatory systems in cells that maintain this balance, and the
theme of this article is that the AMP-activated protein kinase
(AMPK) is the key player in this process.
At ¢rst sight, what is needed is a system that can monitor
the cellular ATP:ADP ratio. However, because adenylate ki-
nase maintains the reaction 2ADPHATP+AMP close to
equilibrium in all eukaryotic cells, the AMP:ATP ratio tends
to vary as the square of the ADP:ATP ratio [1], so that the
former is a more sensitive indicator of cellular energy status
than the latter. By the 1960s a small number of metabolic
enzymes had been found to be regulated directly by AMP
and ATP and, extrapolating from these, Atkinson et al. [2]
proposed that AMP, or the AMP to ATP ratio, would regu-
late enzymes involved at many branch points determining
metabolic choices between anabolism and catabolism. This
hypothesis now appears to be correct, except that what At-
kinson had not anticipated was that in most cases this regu-
lation would be performed by a protein kinase cascade rather
than by direct allosteric regulation of the target enzymes. In
this article we will concentrate on recent studies of the system,
and readers should refer to previous reviews [1,3] for the ear-
lier literature.
2. Structure and regulation of AMPK
AMPKs are heterotrimeric complexes comprising a cata-
lytic K subunit and regulatory L and Q subunits [1,3]. Homo-
logues of these three subunits are found in all eukaryotic
species where genome sequences have been completed (Fig.
1). They are even found in the very primitive eukaryote Giar-
dia lamblia, which does not possess mitochondria, nucleoli, or
peroxisomes, and which according to molecular phylogenies is
more than twice as remote from humans as fungi [4]. This
suggests that the possession of AMPK complexes is a univer-
sal feature of eukaryotes. The number of genes encoding each
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subunit varies from species to species. In the fruit £y Droso-
phila melanogaster, for example, there are single genes encod-
ing homologues of K, L and Q [5], while in humans each sub-
unit is encoded by either two or three distinct genes (K1, K2,
L1, L2, Q1, Q2, Q3), so that there are 12 possible KLQ combina-
tions (even excluding splice variants).
As the name suggests, mammalian AMPK is allosterically
activated by 5P-AMP. However, the complex is inactive unless
it has been phosphorylated by upstream kinases (currently
unidenti¢ed) at a threonine residue (Thr-172) in the ‘activa-
tion segment’ of the kinase domain, and our laboratory
showed that AMP had three additional e¡ects to activate
the system, i.e. (i) activation of the upstream kinase, (ii) mak-
ing AMPK a better substrate for the upstream kinase and
(iii) making it a worse substrate for the protein phosphatase.
The combination of these e¡ects results in the system being
‘ultrasensitive’, i.e. the response curve is sigmoidal and (over
the critical concentration range) a small change in AMP pro-
duces a large e¡ect [6]. The simplest hypothesis is that the
three e¡ects of AMP that are due to binding to AMPK (as
opposed to the upstream kinase) are due to binding at a single
site, although this remains to be proven. All three e¡ects are
antagonised by high concentrations of ATP [7^9], suggesting
that the allosteric site(s) bind AMP and ATP competitively,
and also implying that the key signal that activates AMPK in
vivo is rising AMP coupled with falling ATP.
What are the functions of the three subunits of AMPK?
The K subunit sequences contain an N-terminal kinase do-
main and a C-terminal domain of approximately equal size
(Fig. 2A). When expressed on its own in either bacterial [10]
or mammalian [11] cells, the kinase domain is AMP-indepen-
dent, although it still requires phosphorylation of Thr-172 to
become active. Based on expression of C-terminal truncations,
the extreme C-terminus of K1 (392^548) is required for for-
mation of the complex with the L and Q subunits, while the
region immediately C-terminal to the kinase domain (312^
392) appears to be inhibitory [11].
The L subunits contain poorly conserved N-terminal re-
gions followed by two regions, originally termed KIS and
ASC domains [12], that are conserved across all eukaryotes
(Fig. 2B). Based on two-hybrid analysis in the yeast system, it
was originally thought that the KIS domain was required for
interaction with the K subunit, while the ASC domain was
required for the interaction with Q [12]. However, recent stud-
ies in which the mammalian L subunits were truncated from
the N-terminus and co-expressed with K and Q have modi¢ed
this view: only the ASC domain was required for the forma-
tion of a stable, active KLQ complex [13]. Recent bioinformatic
analysis has also shown that the so-called KIS (kinase
Fig. 1. Phylogenetic trees of homologues of the (A) K subunits,
(B) L subunits and (C) Q subunits of AMPK from di¡erent species.
Species analysed are human (Homo sapiens), fruit £y (Drosophila
melanogaster), nematode worm (Caenorhabditis elegans), slime
mould (Dictyostelium discoideum), thale cress (Arabidopsis thaliana),
budding yeast (Saccharomyces cerevisiae), ¢ssion yeast (Schizosac-
charomyces pombe), and Giardia lamblia. Names of isoforms are
shown where relevant. Most sequences were found using BLAST
searches of the respective genome web sites. Initial alignments were
created using PILEUP and the trees were created using CLUS-
TALX by the neighbour-joining method.
Fig. 2. Diagram showing the location of conserved domains in the
(A) K subunits, (B) L subunits and (C) Q subunits of mammalian
AMPK, and (D) the unusual LQ subunits found in higher plants.
The proposed function of each domain is indicated underneath the
subunit.
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interaction sequence) domain may in fact have a function
other than interaction with the kinase subunit. Its sequence
is closely related to those of ‘N-isoamylase domains’ (see the
PFAM database [14], entry PF02922), which are found in
enzymes that metabolise the K1C6 branch points in K1C4-
linked glucans such as starch and glycogen. In these enzymes
the domains appear not to be catalytic but may instead act to
position the enzymes on the substrate prior to catalysis. Our
laboratory [13] and others [15] have recently obtained evi-
dence that this domain is indeed involved in binding of gly-
cogen. There is evidence that high cellular glycogen represses
activation of AMPK in muscle in vivo [16,17], suggesting that
AMPK can act as a ‘glycogen sensor’ as well as a sensor of
AMP and ATP, and it is tempting to suggest that this involves
the glycogen-binding domain. However, the regulation of pu-
ri¢ed AMPK by glycogen in vitro has not yet been convinc-
ingly demonstrated. Whatever the function of the glycogen-
binding domain, it is conserved in the L subunits across all
eukaryotes.
The Q subunits of AMPK contain N-terminal regions that
in mammals are very variable in both size and sequence, fol-
lowed by four tandem repeats of a motif known as a CBS
domain (Fig. 2C). These domains of about 50^60 amino acids
occur in a variety of di¡erent proteins and in all domains of
life from archaea to eukaryotes ([18], see also the PFAM data-
base [14], entry PF00571). CBS domains invariably occur as
tandem pairs, although the Q subunits of AMPK are unique in
having two pairs. The structure of a pair of domains from a
bacterial IMP dehydrogenase [19] shows that they are inti-
mately associated via hydrophobic interactions and suggests
that a single domain would not be stable. Point mutations in
CBS domains in other proteins cause a variety of human
hereditary diseases [20^24], while six di¡erent point mutations
occurring in the CBS domains of the AMPK Q2 subunit cause
cardiac arrhythmias (ventricular pre-excitation, or Wol¡^Par-
kinson^White syndrome) that can lead to sudden death at a
young age from heart failure [25^28]). These observations in-
dicate that CBS domains have important functions, yet they
are not understood in any case. Using a photoa⁄nity ana-
logue of AMP (8-azido-AMP) we obtained evidence that
binding of the adenosine portion of AMP by the AMPK
complex involves the Q subunit [29]. Since complexes contain-
ing any of the three Q subunit isoforms are activated by AMP,
and the CBS domains are the only regions that are conserved
between them, we believe that they represent the binding sites
for the regulatory nucleotides, AMP and ATP. This hypoth-
esis is currently being addressed in our laboratory.
In the higher plant Arabidopsis thaliana there is an intrigu-
ing variant on the distribution of the domains found in other
species. In both maize and A. thaliana, genes have been found
that encode proteins (denoted LQ in Fig. 1C) containing an N-
terminal KIS domain and a C-terminal ‘Q subunit’ region with
four CBS domains [30] (Fig. 2D). Intriguingly, genome se-
quencing also reveals another L subunit homologue in
A. thaliana (protein ID At2g28060.1, shown as L3 in Fig.
1B) that appears to represent an ASC domain without an
associated KIS domain. However, two genes in A. thaliana
encoding more conventional L subunits with KIS and ASC
domains (denoted L1 and L2 in Fig. 1B) have also been re-
ported [31]. Direct biochemical analysis is required to deter-
mine how these various gene products assemble into com-
plexes in plant cells.
3. Recognition of target proteins by AMPK
The original target proteins identi¢ed for AMPK were the
lipid biosynthetic enzymes 3-hydroxy-3-methylglutaryl-CoA
reductase [32,33] and the ACC1 (K) isoform of acetyl-CoA
carboxylase [34,35]. Comparison of sites phosphorylated on
these and other targets revealed conserved sequence motifs,
especially hydrophobic residues at P35 and P+4 (i.e. ¢ve res-
idues N-terminal, or four residues C-terminal, to the phos-
phorylated amino acid) and a single basic residue at P33 or
P34. The importance of these residues was con¢rmed [36,37]
using a series of variants of two related peptides, one of which
was the SAMS peptide, a 15 residue peptide based on the
sequence around Ser-79 on rat ACC1 that has become the
‘gold standard’ substrate for AMPK assays [38]. The core
recognition motif for AMPK de¢ned by these studies was
Hyd-(Basic, X)-X-X-Ser/Thr-X-X-X-Hyd, where Hyd is a hy-
drophobic residue (Leu, Met, Ile, Phe or Val), Basic is Arg,
Lys or His (which can be at P33 or P34) and ‘X’ is any
amino acid.
Molecular modelling of a peptide substrate bound to the
kinase domain of AMPK (based on crystal structures for
other kinase domains with bound inhibitory peptides) sug-
gested that the interaction might in fact occur over a wider
region of the substrate than this nine residue motif [10]. In
particular, the model suggested that binding of substrate res-
idues N-terminal to the P35 position occurred via an amphi-
pathic helix that ¢ts into a hydrophobic groove on the large
lobe of the kinase. Near the Ser-79 site on ACC1 there are
hydrophobic residues not only at P35 but also at P39, P313
and P316 (Fig. 3A), and these would all lie on the same face
of an K-helix. This model was tested using a recombinant
protein in which residues 60^94 from the rat ACC1 sequence
were expressed in bacteria as a fusion with glutathione
S-transferase [10]. The protein containing the wild type se-
quence was an excellent substrate, while point mutations of
the hydrophobic residues at P35, P39, P313 and P316
caused large decreases in kcat/Km. The predicted hydrophobic
interaction between the methionine at P35 on the substrate
and a leucine (Leu-212) in the hydrophobic groove on the
kinase was con¢rmed by making complementary mutations
that converted it into an electrostatic interaction. Further sup-
port for our model came with the publication of the crystal
structure of human HMG-CoA reductase [39], because the
residues from Gly-860 (P312) to Arg-871 (P31) form three
turns of K-helix, with the side chains of Val-863 (P39) and
Met-867 (P35) pointing outwards into the solvent and there-
fore in a position accessible to interact with the hydrophobic
groove on the kinase.
Our model [10] also suggested that the substrate arginine at
P34 bound to an acidic patch on the kinase domain formed
by Glu-100 and Asp-103, while the histidine in the P36 posi-
tion (the N-terminal residue in the SAMS peptide, and pre-
viously only recognised as a positive determinant for the high-
er plant homologue [40]) bound to another acidic patch
formed by Asp-215 and Asp-217. The importance of these
interactions was con¢rmed by making mutations on both
the substrate and the kinase. The only part of the original
recognition motif whose interaction with the kinase domain
could not be modelled precisely was the P+4 hydrophobic
residue, although we did con¢rm by mutation that glutamine
is accepted at this position, as found in some target proteins,
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e.g. endothelial nitric oxide synthase (eNOS) (Fig. 3B). The
model also suggested that His-82 (at P+3, not previously rec-
ognised as a positive determinant and only found in ACC1
and ACC2) formed an electrostatic interaction with Asp-56
on the small lobe of the kinase domain. This was con¢rmed
by performing ‘charge swap’ mutations. The extended sub-
strate recognition determinants derived from this study (to-
gether with information about the residues on the kinase do-
main with which they interact) are shown in Fig. 3A, and an
alignment of the sequences around a few physiological target
sites in Fig. 3B. The latter reveals that only ACC1 seems to
have all of these determinants, but that most sites have at
least a sub-set of them. It is also interesting that in the
NOS and 6-phosphofructo-2-kinase (PFK2) isoforms the ba-
sic^hydrophobic^basic motif usually found in the P36 to P34
position is displaced towards the phosphorylated serine by
one residue, suggesting that some £exibility in the manner
of substrate binding is allowed.
4. Regulation of AMPK in vivo and in intact cells
Because of its reciprocal regulation by AMP and ATP,
mammalian AMPK is activated in intact cells by any stress
that either increases ATP consumption or inhibits ATP pro-
Fig. 3. A: Alignment of sequences (from humans) around target sites for AMPK on the ACC1 and ACC2 isoforms of acetyl-CoA carboxylase,
HMG-CoA reductase (HMGR), glycogen synthase, hormone-sensitive lipase (HSL), the co-activator p300, the endothelial and neuronal iso-
forms of NO synthase (eNOS and nNOS) and the cardiac and ‘inducible’ isoforms of 6-phosphofructo-2-kinase (PFK2). The phosphorylated
serine is shown in bold and underlined, while basic and hydrophobic residues believed to be involved in recognition are highlighted by under-
lining and bold type respectively. B: Sequence (single letter code) around Ser-79 on rat ACC1, showing the residues involved in recognition by
AMPK, with arrows pointing to the residues (numbered) on the kinase domain with which they are proposed to interact. The phosphorylated
serine is marked with ‘P’ and an arrow. C: View of model of a protein substrate bound to the kinase domain of AMPK [10]. The substrate is
shown as a green backbone ‘ribbon’ with selected side chains shown in ‘wireframe’, while the kinase domain is shown in ‘space¢ll’ mode with
acidic residues in red and hydrophobic residues in orange. This view highlights how the arginine side chain at P34 on the substrate (R75) in-
teracts with an acidic patch formed by Glu-100 (E100) and Asp-103 (D103), while residues N-terminal to it form an amphipathic helix with hy-
drophobic side chains, i.e. Met-74 (M74), Leu-70 (L70), Leu-66 (L66) and Ile-63 (I63) on one face. The helix ¢ts into a hydrophobic groove on
the large lobe of the kinase domain.
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duction. These include heat shock, metabolic inhibitors such
as arsenite or oligomycin, hypoxia or ischaemia, and glucose
deprivation (reviewed in [1], see also [41^43]). These can all be
regarded as pathological stresses, but more recently a number
of more physiological stimuli have been found to activate
AMPK, including exercise and contraction in skeletal muscle
[1] and the peptide hormones, leptin and adiponectin [44,45].
These ¢ndings that the system is activated by exercise, and by
‘adipocytokines’ involved in control of appetite, body weight
and insulin sensitivity, point to its potential importance in the
treatment of the current world-wide ‘epidemic’ of obesity and
type 2 diabetes. Indeed, AMPK is activated in intact cells by
two of the main classes of drug currently used to treat type 2
diabetes, i.e. the biguanides (e.g. metformin) and the thia-
zolidinediones (e.g. rosiglitazone) [41,46,47].
Identi¢cation of targets for the system in vivo required the
development of methods to manipulate the activity of the
system other than cellular stresses that deplete ATP, which
might have many secondary consequences unrelated to
AMPK activation. The ¢rst method available was the incuba-
tion of cells with the nucleoside analogue 5-aminoimidazole-4-
carboxamide (AICA) riboside, which is taken up by cells and
converted to the respective monophosphate, ZMP, an ana-
logue of AMP. While still very widely used, this method is
not completely speci¢c in that ZMP is an e¡ector of other
enzymes that are regulated by AMP, such as phosphorylase
and fructose-1,6-bisphosphatase. Incubation of cells with the
anti-diabetic drug metformin represents a second method to
activate the kinase in intact cells. Metformin does not deplete
ATP and the mechanism by which it activates AMPK remains
unknown [41,47]. However, since it clearly works by a di¡er-
ent mechanism from AICA riboside it is a useful adjunct to
the latter. As yet there are no readily available, speci¢c phar-
macological inhibitors of AMPK, although expression of a
kinase-inactive mutant K subunit acts as a dominant negative
inhibitor. This approach works because the K subunit is un-
stable in the absence of L and Q, so that if an inactive K
mutant is over-expressed it replaces the endogenous, active
K subunit because the maximal level of K subunit expression
is limited by the availability of L and Q [48].
Another approach to studying physiological functions in
vivo is the use of transgenic mice. As yet there are no reports
of K1 knockout mice or of mice lacking both catalytic sub-
units, but results with mice having a germ-line disruption of
the K2 gene have recently been presented [49]. Intriguingly,
they have impaired glucose tolerance (i.e. a larger increase in
blood glucose following oral intake) and impaired insulin sen-
sitivity (i.e. a reduced whole body glucose turnover during a
clamp procedure when insulin is raised but blood glucose kept
constant). These are both diagnostic features of diabetes,
although in other respects the mice do not display typical
features of the disease. In particular, their fasting blood glu-
cose, insulin release by isolated pancreatic islets and insulin-
stimulated glucose uptake by isolated muscles were all nor-
mal. Moreover, the glucose intolerance of the knockout mice
could be rescued by injection of the K-adrenergic blocker,
phentolamine, and catecholamines were increased in urine.
The authors therefore suggested that the e¡ects of the K2
knockout on glucose tolerance and insulin sensitivity were
secondary to an increase in catecholamine release via an un-
known mechanism [49].
A complicating factor with the K2 knockout mice was that
the expression of K1 was up-regulated, at least in muscle [49],
and this might be partly compensating for the lack of K2.
Birnbaum and co-workers have created mice that express,
from a muscle-speci¢c promoter, a kinase-inactive K1 subunit
that acts as a dominant negative mutant (see above) [50,51].
In these ‘quasi-knockout’ mice the AMPK activity in muscle
was undetectable, and results obtained with them are dis-
cussed further below.
5. Downstream targets and physiological role of the AMPK
system in vivo
Some of the well-established downstream target proteins
and pathways for AMPK that have been identi¢ed by the
methods described in Section 4 are summarised in Fig. 4.
As space is limited we will concentrate here on more recent
¢ndings, and previous reviews [1,3] should be consulted for
earlier literature. In line with its proposed role in the manage-
ment of cellular energy status, AMPK activation switches o¡
anabolic pathways and other processes that consume ATP,
while switching on catabolic pathways that generate ATP.
Examples of the former include acute inhibition of lipid bio-
synthesis by phosphorylation and inactivation of key metabol-
ic enzymes such as ACC1 (fatty acid synthesis), glycerol phos-
phate acyl transferase (triacylglycerol synthesis), and HMG-
CoA reductase (cholesterol/isoprenoid biosynthesis). AMPK
also inactivates the muscle isoform of glycogen synthase in
cell-free assays [52], and perfusion of rat hind-limb muscle
with AICA riboside also produces an inactivation of the en-
zyme that appears to be due to phosphorylation, although the
sites modi¢ed have not yet been determined [17]. If AMPK
does phosphorylate glycogen synthase in vivo one might ex-
pect that the enzyme would become inactivated during exer-
cise, but con¢rming this was complicated by the fact that
exercise causes glycogen breakdown, which relieves feedback
inhibition of glycogen synthase by glycogen. However, sub-
jects with McArdle’s disease cannot break down glycogen
rapidly due to a hereditary lack of phosphorylase, so these
Fig. 4. Known physiological target proteins and pathways regulated
by the AMPK system. The list is not exhaustive: other targets have
been proposed but in some cases the evidence is not yet conclusive.
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confounding e¡ects are eliminated. In such subjects, exercise
causes a marked activation of AMPK and concomitant inac-
tivation of glycogen synthase, as expected [53].
Thus, AMPK activation inhibits both lipid and carbohy-
drate biosynthesis, and recently it has also been found to
inhibit protein synthesis in isolated hepatocytes via phosphor-
ylation of elongation factor-2 brought about by an activation
of EF-2 kinase [54]. Although these authors found no e¡ect
on phosphorylation of 4E-BP1 (a protein that regulates ini-
tiation of translation) another group did report that in muscle
of rats injected with AICA riboside, inhibition of protein syn-
thesis correlated with reduced phosphorylation of 4E-BP1 at a
site whose phosphorylation activates initiation of translation
[55]. There was also reduced phosphorylation of other protein
kinases, including mTOR and p70 S6 kinase (at Thr-389).
Phosphorylation of p70 S6 kinase by mTOR at Thr-389 is
thought to be involved in activation of the kinase, leading
to phosphorylation of ribosomal protein S6, thus stimulating
translation of ‘5P-TOP’ mRNAs encoding ribosomal proteins
and elongation factors. A problem with the interpretation of
this paper [55] is that it is di⁄cult to know whether the e¡ects
of AICA riboside were direct e¡ects of muscle or indirect
e¡ects on the levels of other circulating factors. However,
Hue’s group have reported that the amino acid-induced acti-
vation of p70 S6 kinase (involving increased phosphorylation
of Thr-389) in isolated hepatocytes was blocked by AICA
riboside [56].
Another recently identi¢ed target of AMPK is the cystic
¢brosis transmembrane conductance regulator (CFTR), the
product of the gene that is mutated in cystic ¢brosis. CFTR
is a Cl3 channel involved in transepithelial ion transport and
£uid secretion, whose open probability is increased by phos-
phorylation by cyclic AMP-dependent protein kinase. Since
opening and closing of the channel requires turnover of
ATP, and the transepithelial ion transport that it brings about
also requires ATP hydrolysis by the plasma membrane Naþ/
Kþ pump, inhibition of CFTR would conserve ATP. Hallows’
group [57] reported that CFTR interacted with the K subunits
of AMPK and was phosphorylated by AMPK in cell-free
assays. When the two proteins were co-expressed in Xenopus
laevis oocytes the cyclic AMP-stimulated Cl3 conductance
was also reduced. More recently, the same group reported
that activation of AMPK inhibited cyclic AMP-stimulated
Cl3 currents in cells derived from human lung and colon,
and that in several types of secretory epithelia, AMPK was
partly co-localised with CFTR at the apical membrane [58,59].
Examples of the manner in which AMPK activation can
generate ATP by stimulating catabolism include its stimula-
tion of fatty acid oxidation via phosphorylation of ACC2, and
its stimulation of glucose uptake via activation of both glu-
cose transporter (GLUT) 1 and GLUT4 (reviewed in [1], see
also [60]). Although the target protein(s) whose phosphoryla-
tion regulates glucose uptake are not known, AICA riboside-
stimulated glucose uptake by muscle is completely abolished
in the ‘quasi-knockout’ mice lacking functional AMPK [51],
con¢rming that AMPK is involved. Another recently found
mechanism by which ATP generation is increased by AMPK
is the phosphorylation of PFK2, which stimulates the produc-
tion of fructose-2,6-bisphosphate, a physiological activator of
the key enzyme of glycolysis, 6-phosphofructo-1-kinase. There
are four isoforms of PFK2, but only the cardiac isoform and
the so-called inducible isoform are targets for AMPK. Phos-
phorylation of the cardiac isoform represents a mechanism to
stimulate glycolytic production of ATP during ischaemia or
hypoxia in the heart, a new mechanism to explain the classical
‘Pasteur e¡ect’ [42]. Expression of the ‘inducible’ isoform is
switched on in monocytes by bacterial lipopolysaccharide.
Phosphorylation and activation of this isoform by AMPK
[43] may be a mechanism that allows monocytes to produce
more ATP by glycolysis, and thus operate in the often hy-
poxic environment of infected or diseased tissues. Intriguingly,
the ‘inducible’ isoform is also expressed by many tumour cells
[61], suggesting that activation of PFK2 by AMPK could be
partly responsible for their high glycolytic rate (the ‘Warburg
e¡ect’).
Another physiological target of AMPK is NOS, of which
both the endothelial and neuronal isoforms (eNOS and
nNOS) appear to be phosphorylated, although only the for-
mer has been shown to be activated [62]. Phosphorylation of
eNOS has been shown to occur in heart muscle during ischae-
mia [62], and of nNOS in skeletal muscle during exercise [63].
There is evidence that NOS activity is required for the e¡ects
of AMPK on glucose uptake in muscle [64] and, since the
classical e¡ect of nitric oxide is to increase blood £ow by
relaxing vascular smooth muscle, another e¡ect of eNOS
phosphorylation might be to increase the local blood £ow
to hypoxic tissues.
The protein IRS-1, which is phosphorylated by the acti-
vated insulin receptor and then acts as binding site for SH2
domain-containing proteins such as phosphatidylinositol (PI)
3-kinase, is phosphorylated at Ser-789 in cell-free assays by
AMPK, and in a muscle cell line in response to AICA riboside
[65]. This phosphorylation appears to increase the binding of
PI 3-kinase to the protein, thus potentially accentuating e¡ects
of insulin. However, further work is required to con¢rm
whether the insulin signalling pathways downstream of PI
3-kinase are regulated by this mechanism.
Finally, the expression of numerous genes is regulated by
AMPK. In a recent microarray study of the ‘quasi-knockout’
mice expressing dominant negative AMPK in muscle, a total
of 234 genes were up-regulated and 130 down-regulated by
more than two-fold compared with control mice [66]. In
muscle, AMPK activation had already been shown to up-reg-
ulate expression of GLUT4, hexokinase, and mitochondrial
enzymes, and in the case of GLUT4, experiments with mice
expressing a reporter gene from the GLUT4 promoter show
that this is an e¡ect on transcription [67]. Similar changes in
expression of these genes are seen in response to endurance
training, or in response to chronic ATP depletion in muscle by
feeding rodents the creatine analogue L-guanidinopropionic
acid. Recent experiments with the ‘quasi-knockout’ mice ex-
pressing dominant negative AMPK suggest that the e¡ects of
the creatine analogue on mitochondrial biogenesis may be
entirely mediated by AMPK [50] (these mice do not tolerate
exercise well [51], so the e¡ects of endurance training could
not be studied). By up-regulating GLUT4, hexokinase and
mitochondrial biogenesis via the AMPK pathway, regular
aerobic exercise would increase the capacity of muscle to
take up glucose and oxidise glucose and fatty acids, thus mak-
ing the same bout of exercise less of a metabolic stress on
subsequent occasions. Consistent with this, the activation of
AMPK in response to the same level of exercise in both rats
[68] and humans [69] was reduced after a regime of endurance
training.
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In liver cells, activation of AMPK decreases the expression
of enzymes of gluconeogenesis (phosphoenolpyruvate car-
boxykinase and glucose-6-phosphatase), both in cell culture
[70] and in vivo [45]. Since elevated gluconeogenesis is a major
cause of the high blood glucose in type 2 diabetes, this e¡ect is
probably a major factor in the success of AMPK-activating
drugs in treating this condition. Another class of genes that
are switched o¡ in liver are those encoding enzymes of fatty
acid biosynthesis (fatty acid synthase and ACC1) [48]. This
brings us round ‘full circle’ in Fig. 4, and emphasises that
fatty acid synthesis is switched o¡ both acutely (by phosphor-
ylation of ACC1) and chronically (by reduced expression of
fatty acid synthase and ACC1). Fatty acid synthesis can be
regarded as a ‘luxury’ pathway that is used as a means to
store excess calories as fat rather than carbohydrate during
‘times of plenty’, and it is not surprising that it is one of the
pathways that is most sensitive to inhibition by AMPK.
At present, the target proteins for AMPK that are respon-
sible for the e¡ects on gene expression are not known,
although the co-activator p300 is phosphorylated at Ser-89
(shown in Fig. 3) and this reduces its interaction with nuclear
hormone receptors such as peroxisome proliferator-activated
receptor-Q (PPAR-Q) [71]. Moreover, AMPK activation has
also been shown (by unknown mechanisms) to reduce the
expression of several important transcription factors, includ-
ing sterol response element binding protein-1C [46], hepato-
cyte nuclear factor-4K [72], C/EBPK and PPAR-Q [71].
6. Conclusions
Recent work on the AMPK system fully con¢rms the pre-
diction made by Atkinson et al. in 1964 [2] that AMP, or the
AMP:ATP ratio, regulates metabolic choices between anabo-
lism and catabolism. These nucleotides achieve this, however,
not just by direct allosteric regulation of metabolic enzymes as
Atkinson had proposed, but also by activation of a complex
signalling cascade that regulates gene expression as well as the
activity of pre-existing proteins. Since genes encoding K, L and
Q subunits related to those of AMPK occur in all eukaryotic
genomes, this is likely to be an ancient mechanism, and this
also implies that 5P-AMP is an intracellular signal molecule of
importance at least equal to that of its more famous cousin,
cyclic AMP. A caveat here is that attempts to demonstrate the
regulation of non-mammalian homologues of AMPK by
AMP, especially those from yeast and higher plants, have as
yet not been successful. However, we recently reported con-
ditions in which the D. melanogaster homologue is activated
by AMP in cell-free assays and, like the mammalian kinase, it
was found to be activated by hypoxia, oligomycin and glucose
deprivation in intact cells [5]. All eukaryotic Q subunit homo-
logues contain the four CBS domains that we now believe to
represent the AMP-binding sites, and we therefore think that
the question whether non-mammalian homologues of AMPK
are regulated by AMP should be re-examined. Finally,
although there are di¡erences in detail, in many respects the
functions of the mammalian AMPK complex and the yeast
SNF1 complex are similar. The latter is required for the
switch from the fermentative metabolism of glucose (using
glycolysis to generate ATP) to the use of alternative carbon
sources and to oxidative metabolism. Similarly, in mammalian
cells the AMPK complex is not required for anaerobic metab-
olism of endogenous fuel (i.e. glycogen), but it is involved in
up-regulating the uptake of glucose and the oxidative metab-
olism of both glucose and fatty acids.
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